Zyn US shipment volume (pouches) in Q3
Short Answer
Both the model and the market expect Zyn US shipment volume in Q3 to be Above 2.8 billion, with no compelling evidence of mispricing.
1. Executive Verdict
- Shipments likely exceed 3 billion pouches, based on PMI's 205 million can guidance.
- PMI's U.S. investments and 25% increased capacity support higher Q3 volumes.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 3.3 billion | 54.0% | 60.0% | Model higher by 6.0pp |
| Above 3.2 billion | 53.0% | 78.3% | Model higher by 25.3pp |
| Above 3.4 billion | 34.0% | 52.2% | Model higher by 18.2pp |
| Above 3.1 billion | 73.0% | 94.0% | Model higher by 21.0pp |
| Above 2.9 billion | 94.0% | 96.0% | Model higher by 2.0pp |
Current Context
PMI plans to expand its Zyn product offerings in Q3 2026. This includes launching 1.5 mg and 8 mg dry Zyn variants in the U.S. during the quarter [^]. These new dry variants complement the Zyn Ultra (moist) line, which PMI launched in June 2026 [^]. Concurrently, PMI aims to accelerate U.S. investments in the second half of 2026, targeting Zyn brand value maximization and preparing for a future IQOS ILUMA launch [^]. Zyn nicotine pouches have also gained visibility from media reports of NFL player usage on sidelines, prompting league policy reminders [^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
The contract tracking Q3 2026 Zyn US shipment volume experienced a sharp repricing on July 30, 2026. The implied probability of shipments exceeding 2.8 billion pouches surged from 1.0% on July 29 to its current level of 97.0%. This near-vertical price move represents the entirety of the market's significant activity to date. The move occurred on extremely low volume, with only 20 contracts traded in total. This thin liquidity suggests the price reflects the conviction of a few participants rather than a broad market consensus.
This bullish repricing appears to be driven by expectations surrounding Philip Morris International's planned product expansion in Q3. The company is set to launch new 1.5 mg and 8 mg dry Zyn variants in the U.S. during the quarter. These new products follow the introduction of the Zyn Ultra moist line in June 2026. The market sentiment is overwhelmingly positive, pricing in a high probability that these new offerings will accelerate volume growth enough to surpass the contract's threshold. Given the short trading history and abrupt price move, no meaningful support or resistance levels have been established beyond the current ceiling near 97.0%.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📈 July 30, 2026: 16.0pp spike
Price increased from 78.0% to 94.0%
Outcome: Above 3.1 billion
What happened: The primary driver for the 16.0 percentage point spike was likely the traditional news announcement from Philip Morris International (PMI) regarding increased investment in ZYN [^][^]. PMI announced it would significantly increase investment in ZYN in the second half of 2026 to defend market share and introduce new variants like ZYN ULTRA [^][^]. This news, reported around July 22, 2026, likely led investors to anticipate accelerated U.S. ZYN shipment volumes, pushing expectations above the Q2 2026 level of 2.9 billion pouches towards the "Above 3.1 billion" outcome for Q3 [^][^][^][^][^][^]. Based on the provided research, social media activity was not a primary driver for this movement.
📈 July 29, 2026: 77.0pp spike
Price increased from 1.0% to 78.0%
Outcome: Above 3.1 billion
What happened: The provided research does not indicate any specific social media activity or traditional news announcement as the primary driver for the 77.0 percentage point spike in the prediction market for "Zyn US shipment volume (pouches) in Q3" above 3.1 billion on July 29, 2026. Philip Morris International had reported Q2 2026 US ZYN shipments at 2.9 billion pouches, showing sequential growth, but there was no official report confirming a 3.1 billion pouch figure for Q3 2026 as of July 30, 2026 [^][^][^][^]. Given the lack of information linking any specific event or social media post to the market move, social media appears irrelevant based on the provided data.
4. Market Data
Contract Snapshot
This Kalshi prediction market resolves to YES if the Zyn US shipment volume (pouches) in Q3 exceeds the specific billion-pouch threshold stated in the contract, and resolves to NO if it is at or below that threshold. Trading concludes on October 20, 6:00 AM EDT, with the maximum payout date listed as February 16, 2027. No special settlement conditions are explicitly mentioned.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 2.8 billion | $0.99 | $0.04 | 97% |
| Above 2.9 billion | $0.98 | $0.08 | 94% |
| Above 3 billion | $0.98 | $0.08 | 93% |
| Above 3.1 billion | $0.79 | $0.29 | 73% |
| Above 3.3 billion | $0.59 | $0.46 | 54% |
| Above 3.2 billion | $0.59 | $0.48 | 53% |
| Above 3.4 billion | $0.38 | $0.69 | 34% |
Market Discussion
As of July 30, 2026, Philip Morris International (PMI) had not released its Q3 2026 financial results, and current expert-curated sources contain no specific data or prediction market discussion regarding Zyn U.S. shipment volume for that quarter [^][^][^]. Despite this, prediction markets actively bet on Zyn U.S. shipment volume benchmarks for other quarters, and historical data indicates strong growth in 2025, with Q3 2025 shipment volume reaching 205 million cans (approximately 3.075 billion pouches) [^][^][^][^][^].
5. What are the consensus analyst estimates for Philip Morris International's Zyn shipment volume in the U.S. for Q3 2026?
| Zyn US shipment volume Q3 2026 | Approximately 205 million cans [^][^] |
|---|---|
| Zyn US total volume 2026 | Exceed 700 million cans [^][^] |
| Zyn US shipment volume Q2 2026 | Approximately 180 million cans [^][^] |
Consensus analyst estimates for U.S. Zyn shipment volume in Q3 2026 are not explicitly available. The provided research does not detail specific consensus analyst projections for Philip Morris International's Zyn shipment volume in the United States for the third quarter of 2026.
Philip Morris's internal guidance projects approximately 205 million U.S. Zyn cans for Q3 2026. Philip Morris International's internal projections indicate an estimated U.S. Zyn shipment volume of approximately 205 million cans for Q3 2026 [^][^]. The company anticipates its total U.S. Zyn volume for the entire year of 2026 to exceed 700 million cans. This comprehensive 2026 projection includes an estimated 180 million cans in Q2, 205 million in Q3, and 200 million in Q4 [^][^].
6. What is the projected impact of the new Zyn Ultra, 1.5 mg, and 8 mg variants on Philip Morris International's total U.S. shipment volume for Q3 2026?
| Projected Q3 2026 U.S. ZYN Shipments | Approximately 205 million cans [^][^] |
|---|---|
| Q3 2025 Promotional Volume | About 250 million pouches [^][^] |
| New ZYN Variants Launching Q3 2026 | 1.5 mg, 8 mg dry, ZYN ULTRA (9 mg and 11 mg moist) [^][^][^][^] |
Philip Morris International (PMI) anticipates 205 million ZYN cans for Q3 2026. PMI projects its underlying U.S. ZYN shipment volume for the third quarter of 2026 to be approximately 205 million cans [^][^]. This projected volume faces challenging year-over-year comparisons due to substantial one-off promotional activity in Q3 2025, which amounted to about 250 million pouches [^][^].
Philip Morris is expanding its ZYN portfolio with new variants. PMI plans to enhance its ZYN portfolio by launching 1.5 mg and 8 mg dry variants in the U.S. during the third quarter of 2026 [^][^][^][^]. These new offerings will complement the recently introduced ZYN ULTRA, which includes 9 mg and 11 mg moist variants [^][^][^][^]. Management anticipates that this expanded product offering will boost the dynamism of ZYN and support brand equity in the second half of 2026 [^]. However, specific quantified volume impact projections for these new variants in Q3 2026 have not been publicly disclosed, therefore, the precise numerical contribution to PMI's total U.S. shipment volume cannot be determined from the available information [^].
7. How did Zyn's U.S. market share and volume growth in H1 2026 compare to its primary competitor, British American Tobacco's Velo brand?
| ZYN Q1 2026 U.S. Shipments | Fell 23.5% [^][^][^] |
|---|---|
| ZYN Q2 2026 U.S. Shipments | Increased 1.8% to 2.9 billion pouches [^][^][^] |
| Velo U.S. Modern Oral Volume Share | Increased 10.4 percentage points [^][^][^] |
ZYN faced initial challenges but showed recovery in the first half of 2026. U.S. shipments for ZYN declined by 23.5% in the first quarter, attributed to inventory adjustments. However, the brand demonstrated sequential improvement in the second quarter, with U.S. shipments increasing by 1.8% to 2.9 billion pouches. Overall, ZYN's offtake volumes were reported as broadly stable to slightly growing during this period [^][^][^].
Velo achieved significant U.S. market share growth in the first half of 2026. British American Tobacco's Velo brand delivered an "excellent" performance in the U.S. during this period, notably driven by Velo Plus. This success contributed to a substantial 10.4 percentage point increase in the total volume share of Modern Oral products in the U.S. [^][^][^].
Philip Morris plans increased ZYN investments to boost competitiveness after uneven competition. Following a period of fluctuating competition, Philip Morris International intends to accelerate its U.S. investments for ZYN in the second half of 2026. These planned investments aim to strengthen brand equity, expand ZYN's product portfolio, and enhance its competitive standing in the market [^][^][^][^].
8. Are Nielsen or IRI retail scanner data for nicotine pouch sales available for July and August 2026, and what early trends do they indicate for Zyn?
| Zyn U.S. pouch sales data July-Aug 2026 | No public datasets available (NielsenIQ, Circana) [^][^][^][^][^][^][^][^][^] |
|---|---|
| Full August 2026 data availability | Not until September 2026 (NielsenIQ, Circana) [^][^][^] |
| Partial July 2026 data availability | Likely late July 2026 (NielsenIQ, Circana) [^][^][^] |
Public Zyn nicotine pouch sales data for July and August 2026 is unavailable. No public datasets containing Zyn nicotine pouch sales data for July and August 2026 were found in the provided sources. While proprietary NielsenIQ and Circana retail scanner data are likely to exist, they are not publicly available. Public commentary suggests a high-level positive trend for Zyn; however, specific monthly growth details for July and August 2026 cannot be confirmed from the available information [^][^][^][^][^][^][^].
Retail scanner data typically exhibits reporting lags for brand-specific sales. NielsenIQ and Circana retail scanner data typically have a reporting lag, meaning full August 2026 data would not be available until September 2026, and partial July 2026 data would likely be available by late July 2026. However, no public Nielsen or Circana/IRI retail scanner dataset for Zyn U.S. pouch sales in July or August 2026 was found in the evidence. These scanner feeds are generally proprietary, and while companies like Philip Morris International and Altria often cite Nielsen or Circana-based estimates in investor materials, they do not publish the underlying brand-level tables for these specific months [^][^][^][^][^][^][^][^][^].
General indicators suggest a positive trend for Zyn despite lacking specific monthly data. Based on public proxies, the early signal for Zyn remains positive at a high level. Philip Morris International materials reference Nielsen-estimated Zyn offtake growth, and public statements from an FDA transcript indicate monthly pouch sales continue to rise in Nielsen data [^][^][^][^][^][^][^]. Nevertheless, without a public scanner data cut for July or August 2026, it is not possible to confirm whether Zyn’s growth accelerated, slowed, or held steady during this specific period [^][^][^][^][^][^].
9. Based on PMI's Q2 2026 earnings call, what is the company's official guidance for Zyn's growth and U.S. investments in the second half of 2026?
| ZYN US shipment volume guidance Q3 2026 | No specific numerical guidance provided (PMI) [^][^][^][^][^] |
|---|---|
| ZYN US shipment volume Q2 2026 | 2.9 billion pouches (PMI) [^][^][^][^][^][^][^] |
| Promotional comparison September 2025 | Around 250 million pouches (PMI) [^][^][^] |
PMI plans significant ZYN U.S. investments to drive second-half growth. The company did not issue specific numerical guidance for ZYN U.S. shipment volumes for Q3 2026. Instead, PMI announced intentions to accelerate U.S. investments in the latter half of 2026, anticipating that ZYN's growth will be bolstered by an expanded product portfolio and increased commercial activities [^][^][^][^][^]. The company's official guidance indicates that these enhanced commercial efforts and portfolio expansion are expected to boost ZYN's dynamism [^][^][^]. PMI's full-year outlook remains stable to slightly growing total volumes, prioritizing ZYN's long-term brand equity and portfolio development [^][^].
Investments will support ZYN's expanded product portfolio, including new variants. These accelerated investments, planned for the second half of 2026, will specifically support the expanded ZYN portfolio. This expansion includes new ZYN ULTRA variants and forthcoming 1.5mg and 8mg dry variants [^][^][^]. The strategy aims to maximize ZYN's long-term brand value and prepare for the potential future introduction of IQOS ILUMA in the U.S. market [^][^][^].
ZYN's Q2 shipment volumes increased, but Q3 comparisons face challenges. In Q2 2026, ZYN U.S. shipment volume reached 2.9 billion pouches, reflecting a year-on-year increase of 1.8% to 2% [^][^][^][^][^][^][^]. Management noted that Q3 year-over-year comparisons would be challenging due to a one-off promotional comparison from September 2025, involving approximately 250 million pouches [^][^][^].
10. What Could Change the Odds
Key Catalysts
Philip Morris International (PMI) is scheduled to report its Q3 2026 earnings on August 10, 2026 [^] . The company projected Q3 2026 U.S. ZYN shipment volume at approximately 205 million cans [^].
Key bullish catalysts include continued strong consumer offtake and an expanded manufacturing capacity, targeting a 25% increase by mid-2026 [^] . Successful portfolio expansion with new ZYN variants further supports this outlook [^].
Key Dates & Catalysts
- Expiration: February 17, 2027
- Closes: February 17, 2027
11. Decision-Flipping Events
- Trigger: Philip Morris International (PMI) is scheduled to report its Q3 2026 earnings on August 10, 2026 [^] .
- Trigger: The company projected Q3 2026 U.S.
- Trigger: ZYN shipment volume at approximately 205 million cans [^] .
- Trigger: Key bullish catalysts include continued strong consumer offtake and an expanded manufacturing capacity, targeting a 25% increase by mid-2026 [^] .
13. Historical Resolutions
Historical Resolutions: 11 markets in this series
Outcomes: 0 resolved YES, 0 resolved NO
Recent resolutions:
- KXPM-26JULZYNSHIP-210000000: SCALAR (Jul 24, 2026)
- KXPM-26JULZYNSHIP-205000000: SCALAR (Jul 24, 2026)
- KXPM-26JULZYNSHIP-200000000: SCALAR (Jul 24, 2026)
- KXPM-26JULZYNSHIP-195000000: SCALAR (Jul 24, 2026)
- KXPM-26JULZYNSHIP-190000000: SCALAR (Jul 24, 2026)
